Madrigal Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Madrigal Pharmaceuticals Inc cash flow-to-debt ratio. Madrigal Pharmaceuticals Inc (MDGL) has a Cash Flow-to-Debt Ratio of -0.20x as of December 2025, meaning its operating cash flow of $-133.46 Million could theoretically repay 0% of its total liabilities ($656.90 Million) in one year. Check Madrigal Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Madrigal Pharmaceuticals Inc (2003–2025)
Cash flow-to-debt ratio of Madrigal Pharmaceuticals Inc from 2003 to 2025. Historical debt coverage capacity for Madrigal Pharmaceuticals Inc across 23 annual periods. Check Madrigal Pharmaceuticals Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Madrigal Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2003–2025)
Madrigal Pharmaceuticals Inc cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Madrigal Pharmaceuticals Inc. For the full cash flow conversion analysis, see MDGL operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.29x | $-189.55 Million | $656.90 Million | ▲ +81.8% |
| 2024 | -1.58x | $-455.57 Million | $287.86 Million | ▼ -14.8% |
| 2023 | -1.38x | $-324.23 Million | $235.21 Million | ▼ -1.3% |
| 2022 | -1.36x | $-224.86 Million | $165.18 Million | ▲ +42.8% |
| 2021 | -2.38x | $-183.92 Million | $77.22 Million | ▲ +28.9% |
| 2020 | -3.35x | $-157.56 Million | $47.02 Million | ▼ -105.2% |
| 2019 | -1.63x | $-41.62 Million | $25.49 Million | ▲ +45.9% |
| 2018 | -3.02x | $-25.51 Million | $8.44 Million | ▼ -36.1% |
| 2017 | -2.22x | $-22.32 Million | $10.05 Million | ▲ +39.5% |
| 2016 | -3.67x | $-17.61 Million | $4.80 Million | ▲ +8.7% |
| 2015 | -4.02x | $-71.44 Million | $17.79 Million | ▼ -80.9% |
| 2014 | -2.22x | $-78.92 Million | $35.54 Million | ▼ -32.3% |
| 2013 | -1.68x | $-77.41 Million | $46.11 Million | ▲ +13.3% |
| 2012 | -1.94x | $-54.13 Million | $27.95 Million | ▼ -12.8% |
| 2011 | -1.72x | $-47.30 Million | $27.55 Million | ▼ -37.5% |
| 2010 | -1.25x | $-38.20 Million | $30.59 Million | ▼ -11.8% |
| 2009 | -1.12x | $-26.81 Million | $24.00 Million | ▼ -359.5% |
| 2008 | -0.24x | $-37.94 Million | $156.04 Million | ▼ -187.3% |
| 2007 | 0.28x | $27.22 Million | $97.75 Million | ▲ +129.7% |
| 2006 | -0.94x | $-52.98 Million | $56.54 Million | ▲ +71.6% |
| 2005 | -3.30x | $-61.88 Million | $18.73 Million | ▼ -37.5% |
| 2004 | -2.40x | $-33.80 Million | $14.06 Million | ▲ +64.4% |
| 2003 | -6.75x | $-23.61 Million | $3.50 Million | — |